a Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, Key Laboratory of Technology of Drug Preparation (Zhengzhou University), Ministry of Education of China, Key Laboratory of Henan Province for Drug Quality and Evaluation, School of Pharmaceutical Sciences , Zhengzhou University , Zhengzhou , PR China.
J Biomol Struct Dyn. 2019 Aug;37(13):3482-3495. doi: 10.1080/07391102.2018.1518158. Epub 2018 Dec 5.
Lysine-specific demethylase 1 (LSD1) was regarded as a promising anticancer target for the novel drug discovery. In this work, we carried out a molecular modeling study on the substituted pyridine derivatives as LSD1 inhibitors using three-dimensional quantitative structure-activity relationship (3D-QSAR), molecular docking and molecular dynamics (MD) simulations. Molecular docking studies predicted the probable binding mode of ligands, and suggested Lys661 and Asp555 might be key residues. Our 3D-QSAR models exhibited satisfactory internal and external predicted capacity. For the comparative molecular field analysis (CoMFA) model, its training set had of 0.595 and of 0.959, while test set had of 0.512 and of 0.846. For the best comparative molecular similarity indices analysis (CoMSIA) model, its training set had of 0.733 and of 0.982, while test set had of 0.695 and of 0.922. MD simulations result revealed the detailed binding process and found an important conserved water-bridge motif between ligands and protein. The binding free energies calculation using Molecular Mechanics Poisson-Boltzmann Surface Area (MM-PBSA) approach coincided well with the experimental bioactivity and demonstrated that the electrostatic interaction was the major driving force for binding. The energy decomposition pointed out some significant residues (Asp555, Lys661, Trp695, Tyr761 and FAD) for the LSD1 potency increase. Based on these results, five new inhibitors were designed, and their activities were predicted using our 3D-QSAR models. Communicated by Ramaswamy H. Sarma.
赖氨酸特异性脱甲基酶 1(LSD1)被认为是一种有前途的抗癌药物靶点,用于新型药物发现。在这项工作中,我们使用三维定量构效关系(3D-QSAR)、分子对接和分子动力学(MD)模拟,对取代吡啶衍生物作为 LSD1 抑制剂进行了分子建模研究。分子对接研究预测了配体的可能结合模式,并提出 Lys661 和 Asp555 可能是关键残基。我们的 3D-QSAR 模型表现出令人满意的内部和外部预测能力。对于比较分子场分析(CoMFA)模型,其训练集的相关系数(r2)为 0.595,外部验证集的相关系数(r2cv)为 0.959;对于最佳比较分子相似性指数分析(CoMSIA)模型,其训练集的相关系数(r2)为 0.733,外部验证集的相关系数(r2cv)为 0.982。MD 模拟结果揭示了详细的结合过程,并发现配体与蛋白质之间存在一个重要的保守水桥模体。使用分子力学泊松-玻尔兹曼表面面积(MM-PBSA)方法计算的结合自由能与实验生物活性吻合良好,表明静电相互作用是结合的主要驱动力。能量分解指出了一些对 LSD1 活性增加有重要意义的残基(Asp555、Lys661、Trp695、Tyr761 和 FAD)。基于这些结果,设计了五个新的抑制剂,并使用我们的 3D-QSAR 模型预测了它们的活性。由 Ramaswamy H. Sarma 交流。